- 生物制剂表现 -
The tools for creating novel biologics have resulted in a broad array of constructs with new modes of action and improved efficacy that are advancing to the clinic. The Fifth Annual Display of Biologics track showcases innovation in discovery, design and engineering of biologics through molecular evolution using phage, yeast and other display methodologies. Insights will be shared on using big data strategies and informatic analysis of next-generation sequencing outputs to improve library design and optimize drug molecules with greater potency, specificity, modes of action and activity than previously achievable.


Preliminary Agenda


Plenary Keynote Session

Moderator's Opening Remarks

Janine Schuurman, PhD, Corporate Vice President, Research & Innovation, Genmab BV

Bicycles and Bicycle Drug Conjugates

Sir Gregory Winter, PhD, FRS, Master, Trinity College; Co-Founder and Director, Bicycle Therapeutics

Using Protein Engineering to Make Therapeutics in Situ

Andreas G. Plückthun, PhD, Professor and Director, Department of Biochemistry, University of Zürich

NOVEL TOOLS FOR TARGET DISCOVERY

Yeast Surface Display Platform for Rapid Discovery of Conformationally Selective Nanobodies
Andrew C. Kruse, PhD, Associate Professor, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School

Back to the Future: Bacteriophages as Promising Therapeutic Tools
Pilar Domingo-Calap, PhD, Postdoctoral Researcher, Department of Genetics, Institute for Integrative Systems Biology, University of Valencia

Phage Display as a Tool for Bispecific Antibody Generation
Andrew Nixon, PhD, Vice President, Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceuticals, Inc.

THERAPEUTIC APPROACHES TO AUTOIMMUNE DISEASE AND BEYOND

Antibody Discovery at Bayer beyond Oncology
Rene Hoet, PhD, Head, Antibody Lead Discovery, Bayer AG

Discovering Antibodies against Challenging Epitopes and Challenging Antigens
Ruud de Wildt, PhD, Director, Head of Lead Discovery, Biopharm, GlaxoSmithKline

NOVEL USES OF DISPLAY TECHNOLOGIES

Discovery of a Cryptic Peptide Binding Site on PCSK9 and Design of Antagonists
Yingnan Zhang, PhD, Senior Scientific Manager, Early Discovery Biochemistry, Genentech

Microfluidics and Genomics for Polyclonal and Monoclonal Antibody Drugs for Infectious Disease
David S. Johnson, PhD, Founder and CEO, GigaGen, Inc.

COMPLEX SELECTIONS AND LIBRARIES

KEYNOTE PRESENTATION: Single Cell Selections of Recombinant Antibodies Binding to Circulating Tumor Cells
Peter Kristensen, PhD, Associate Professor, Department of Chemistry and Bioscience Aalborg University

Dual Display: Phage Selection Driven by Co-Engagement of Two Targets
Oliver Hartley, PhD, Associate Professor, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva

Phage Display Selection of Chemically Cyclized Peptides for the Development of Therapeutics
Christian Heinis, PhD, Professor, Laboratory of Therapeutic Peptides and Proteins, Ecole Polytechnique Federal de Lausanne (EPFL)

EMPOWERING NOVEL THERAPIES

Virus-Like Particle Display of HER2 Induces Potent Anti-Cancer Responses
Arianna Palladini, PhD, University of Bologna
Susan Thrane, MSc, PhD, Postdoc, Institute for Immunology and Microbiology, Centre for Medical Parasitology, Copenhagen University

KEYNOTE PRESENTATION: From Systems Biology to Systems Biologics
Sachdev Sidhu, PhD, Professor, Molecular Genetics, The Donnelly Centre, University of Toronto

Sponsored Presentations

Further Advancement for Human ab Discovery
Vera Molkenthin, PhD,Chief Scientist, AbCheck

Screening Smarter to Derive Data Driven Decisions Faster
Sarah Payne, PhD, Product Manager, Marketing, TTP Labtech

Validation of llamdA, Isogenica's Humanized Single Domain Antibody Library
Guy Hermans, PhD, CSO, Isogenica Ltd


* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English